Register now!
Login
OCTOBER 9-10, 2025
Professional HUB Hannover Medical Park
Hannover, Germany
Scientific Program | Delta Cure - 4th International Meeting |...
On this page you will find the Scientific Program of the Delta...
Scientific Program
| WHO Symposium on HDV epidemiology | |
| 11.00-11.15 | Recent published literature on HDV epidemiology |
| 11.15-12.15 | Brief overview about HDV epidemiology in Moldavia, Africa, Central Asia, South America and Pakistan |
| 12.15-12.30 | Roundtable discussion |
| 12.30-13.30 | Light lunch |
| Opening Session | |
| 13.30-13.45 | Welcome by the Chairs and the Scientific Committee |
| SESSION 1 | Pathophysiology: Virology and Immunology |
| 13.45-14.00 | What’s new in HDV virology and immunology? |
| 14.00-14.15 | Preclinical models for HDV – from organoids to humanized mice |
| 14.15-14.25 | Oral presentation Abstract No 1To be selected |
| 14.25-14.35 | Oral presentation Abstract No 2To be selected |
| 14.35-14.50 | Poster summaries |
| 14.50-15.15 | Panel discussion: Unmet needs in translational HDV research |
| 15.15-16.15 | Coffee break and Poster Session No 1 with guided Poster Tour |
| SESSION 2 | Diagnostic and Natural History |
| 16.15-16.30 | What’s new in HDV natural history? |
| 16.30-16.45 | What’s new in HDV diagnostics? |
| 16.45-17.00 | Role of HBV biomarkers in HDV |
| 17.00-17.10 | Oral presentation Abstract No 3To be selected |
| 17.10-17.20 | Oral presentation Abstract No 4To be selected |
| 17.20-17.30 | Oral presentation Abstract No 5To be selected |
| 17.30-17.45 | Poster summaries |
| 17.45-18.00 | Panel discussion |
| 18.00-18.15 | Break |
| 18.15-19.00 | Special Talk and Award SessionPresentation of the Delta Cure Award 2025 |
| 20.00 | Networking Dinner |
| SESSION 3 | Current treatment options |
| 08.30-08.45 | BLV Real-World data |
| 08.45-09.00 | BLV: when to stop? Lessons learned from clinical trials |
| 09.00-09.10 | Oral presentation Abstract No 6To be selected |
| 09.10-09.20 | Oral presentation Abstract No 7To be selected |
| 09.20-09.30 | Oral presentation Abstract No 8To be selected |
| 09.30-09.45 | Poster summaries |
| 09.45-10.00 | Discussion |
| 10.00-11.00 | Coffee break and Poster Session No 2 with guided Poster Tour |
| SESSION 4 | Drugs in development |
| 11.00-11.15 | What have we learned from lonafarnib and PEG-lambda trials? |
| 11.15-11.30 | Anti-HBs monotherapy for HDV infection |
| 11.30-11.45 | Anti-HBs and siRNAs: Update 2025 |
| 11.45-11.55 | Oral presentation Abstract No 9To be selected |
| 11.55-12.05 | Oral presentation Abstract No 10To be selected |
| 12.05-12.20 | Novel TLRs, NAPs, Vaccines, other entry inhibitors |
| 12.20-12.35 | New developments in HBV drug development including genome and epigenomic editing – relevance for HDV? |
| 12.35-12.50 | Discussion |
| 12.50-13.45 | Light Lunch |
| SESSION 5 | The future and unmet needs of Hepatitis Delta |
| 13.45-13.55 | Oral presentation late Breaking AbstractTo be selected |
| 13.55-14.10 | New EASL HBV Guidelines: Implications for Hepatitis D |
| 14.10-15.00 | Roundtable discussionFaculty representatives, patient representatives, representatives from diagnostics and health industry, and the Delta Cure audience for Science |
| 15.00-15.10 | Farewell |
